Search for content, post, videos

Moberg Pharma granted patent in China


The company’s MOB-015 has been granted patent protection in China, valid until 2032.

MOB-015 is an internally developed topical formulation of terbinafine for the treatment of onychomycosis, currently under clinical development in phase 3. MOB-015’s patent protection thus covers the key markets for commercialization. Moberg Pharma has previously been granted patent protection for MOB-015 in EU, US and Canada among others.

“Having been granted the Chinese patent means we now cover the main markets in which we are planning to commercialize MOB-015. It is an important milestone in our strategy to establish a broad patent protection for our proprietary products,” says Peter Wolpert, Moberg Pharma’s CEO.

Under clinical development

MOB-015 is under clinical development in phase 3. Studies are progressing in the EU and North America with first topline-results expected in the fourth quarter of 2019. In September this year, the enrollment to the North American study was completed, including in total 365 patients, randomized at 32 sites in the U.S. and Canada. As for the European study, screening and randomization of patients is expected to be completed by the beginning of 2019, with topline-results around 15 months later.

Moberg Pharma estimates the global peak sales potential for MOB-015 to be in the range of USD 250-500 million. The recent license agreement with Cipher Pharmaceuticals in Canada confirms the market potential for MOB-015. Under the agreement, Moberg Pharma is entitled to milestones of USD 14.6 million in addition to attractive royalties on net sales.

Photo of Peter Wolpert: Moberg Pharma